AMD is a progressive retinal disease affecting older adults, and the leading cause of irreversible blindness in the western world affecting millions. Symptoms, including blurry vision, loss of night vision and loss of central vision, make activities of daily living such as reading, driving and even recognizing faces more difficult over time.
From Genetics, a New Path Forward
Dry AMD results from an interaction of both environmental and genetic risk factors. Aging and smoking confer the strongest non-genetic risk, but genetic risk is significant, with approximately 70% attributable risk of advanced disease due to heritability. Research over the last decade has uncovered multiple genetic variants which can increase risk of developing advanced AMD by up to 20-fold. Gemini Therapeutics is examining many of these genetic variants through CLARITY, its natural history study in people with dry AMD.
Most AMD patients have the dry form of AMD — for which there are no approved therapies. Dry AMD affects the vision that patients use to see grandchildren’s faces or to read. This is the essential form of vision that Gemini Therapeutics is trying to preserve in a targeted way.